Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03413956
Other study ID # JS-LC-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 1, 2017
Est. completion date March 30, 2018

Study information

Verified date May 2018
Source Jiangsu Cancer Institute & Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The real-world observational study was designed to explore the odd factors of lymph metastases in the patients with T1 non-small cell lung cancer, the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.


Description:

The trial is a multi-centre, real-world non-interventional observational study. In the study, the patients with T1 non-small cell lung cancer enrolled in clinics from 2015 to 2017 were included via a retrospectively review method and the study data on patient demographic/tumor biological characteristics, and clinical treatments were collected to explore the clinical odd factors of lymph metastases, evaluate the effects of clinical characteristics on lymph metastases, and compare the differences in lymph metastases in the subgroups.


Recruitment information / eligibility

Status Completed
Enrollment 10885
Est. completion date March 30, 2018
Est. primary completion date March 30, 2018
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients who received surgeries from 2015 to 2017;

- Pathologically diagnosed patients with T1 non-small cell lung cancer;

Exclusion Criteria:

- Patients with tumor treatments (including chemotherapies, radiotherapies, biological therapies, intervention therapies)

Study Design


Intervention

Procedure:
Surgeries
Surgeries

Locations

Country Name City State
China China People's Liberation Army Hospital Beijing Beijing
China China-Japan Friendship Hospital Beijing Beijing
China West China Hospital Chengdu Sichuan
China First Hospital Affiliated to Medical College, Zhejiang University Hangzhou Zhejiang
China Jiangsu Cancer Institute and Hospital Nanjing Jiangsu
China Shanghai Chest Hospital Shanghai Shanghai
China Tongji Hospital Affiliated to Tongji Medical College, Huaxi Technology University Wuhan Hubei
China Xi'an Tangdu Hospital Xi'an Shaanxi
China Henan cancer hospital Zhengzhou Henan
China Henan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Cancer Institute & Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Percentage of N2 patients with lymph nodes Percentages of N2 patients with lymph nodes in N2 population 2015 - 2017
Other Percentage of patients with lymph metastases categorised by tumor baseline characteristics Percentage of patients with lymph metastases categorised by tumor baseline characteristics 2015 - 2017
Other Number of lymph nodes in N2 patients Number of lymph nodes in N2 patients categorised by tumor baseline characteristics 2015 - 2017
Other Percentage of patients with N2 skip metastases Percentage of patients with N2 skip metastases categorised by tumor baseline characteristics 2015 - 2017
Primary Percentage of the patients with lymph metastases Percentages of the patients with lymph metastases categorised by patient demographic and tumor biological characteristics 2015 - 2017
Secondary Percentages of N0/N1/N2/N3 patients Percentages of N0/N1/N2/N3 patients in the target population 2015 - 2017
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Completed NCT01945021 - Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC Phase 2
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Terminated NCT04022876 - A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) Phase 1
Recruiting NCT05898763 - TEIPP Immunotherapy in Patients With NSCLC Phase 1/Phase 2
Recruiting NCT05532696 - Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/Phase 2
Completed NCT04311034 - A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03177291 - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC Phase 1
Terminated NCT03257722 - Pembrolizumab + Idelalisib for Lung Cancer Study Phase 1/Phase 2
Completed NCT00349089 - Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy Phase 2
Completed NCT05116891 - A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04571632 - Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors Phase 2
Terminated NCT03599518 - DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Phase 1
Not yet recruiting NCT06020989 - Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy Phase 2
Withdrawn NCT03982134 - PDR001 + Panobinostat for Melanoma and NSCLC Phase 1
Withdrawn NCT03574649 - QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer Phase 2
Withdrawn NCT02844140 - DE-CT in Lung Cancer Proton Therapy N/A
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1